Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?

Luke J. Vano,Mattia Veronese,Robert A. McCutcheon,Oliver D. Howes
DOI: https://doi.org/10.1176/appi.ajp.20240278
IF: 17.7
2024-06-02
American Journal of Psychiatry
Abstract:Approximately one-third of patients with schizophrenia do not receive meaningful benefits from first-line antipsychotics (1). When this occurs despite two or more adequate treatment episodes with different antipsychotics, it is termed treatment-resistant schizophrenia (1). Treatment-resistant schizophrenia is associated with reduced quality of life and substantial economic cost to the individual and society (2). Clozapine is the only licensed medication for treatment-resistant schizophrenia, and early use is linked to markedly improved outcomes (3). However, currently the only way to identify treatment resistance is through a series of therapeutic trials with first-line antipsychotics, which often delays clozapine treatment by years, exposes patients to side effects and other risks, and increases costs (4). Treatment of schizophrenia would be revolutionized if we had a biomarker to allow for the early identification of patients with treatment-resistant schizophrenia.
psychiatry
What problem does this paper attempt to address?